| Bioactivity | PCI-33380 is an irreversible and selective Bruton's Tyrosine Kinase (BTK) inhibitor (fluorescent probe). | ||||||||||||
| Target | BTK. | ||||||||||||
| Invitro | PCI-33380 bound to Btk could be detected by denaturing gel electrophoresis and fluorescent gel scanning[2]. Immunofluorescence[2] Cell Line: | ||||||||||||
| Name | PCI-33380 | ||||||||||||
| CAS | 1022899-36-0 | ||||||||||||
| Formula | C46H52BF2N11O3 | ||||||||||||
| Molar Mass | 855.78 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Zuo Y, et al. A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase. Sci Rep. 2015 Nov 4;5:16136. [2]. Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80. |